ArticleESMO gastrointestinal oncology2026

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

D Ciardiello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.